[go: up one dir, main page]

MA45780A - Méthodes de traitement du cancer de la prostate - Google Patents

Méthodes de traitement du cancer de la prostate

Info

Publication number
MA45780A
MA45780A MA045780A MA45780A MA45780A MA 45780 A MA45780 A MA 45780A MA 045780 A MA045780 A MA 045780A MA 45780 A MA45780 A MA 45780A MA 45780 A MA45780 A MA 45780A
Authority
MA
Morocco
Prior art keywords
prostate cancer
treatment methods
treatment
methods
prostate
Prior art date
Application number
MA045780A
Other languages
English (en)
Other versions
MA45780B1 (fr
Inventor
Marco Gottardis
Rebecca Hawkins
Linda Snyder
Douglas H Yamada
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA45780A publication Critical patent/MA45780A/fr
Publication of MA45780B1 publication Critical patent/MA45780B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA45780A 2016-07-29 2017-07-28 Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate MA45780B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US201662369239P 2016-08-01 2016-08-01
EP17754226.3A EP3490560B1 (fr) 2016-07-29 2017-07-28 Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate
PCT/US2017/044413 WO2018023017A1 (fr) 2016-07-29 2017-07-28 Méthodes de traitement du cancer de la prostate

Publications (2)

Publication Number Publication Date
MA45780A true MA45780A (fr) 2019-06-05
MA45780B1 MA45780B1 (fr) 2025-03-28

Family

ID=59649991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45780A MA45780B1 (fr) 2016-07-29 2017-07-28 Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate

Country Status (32)

Country Link
US (8) US20180028521A1 (fr)
EP (2) EP3490560B1 (fr)
JP (3) JP2019522032A (fr)
KR (2) KR20190033599A (fr)
CN (3) CN119606966A (fr)
AU (2) AU2017302660B2 (fr)
BR (1) BR112019001398A2 (fr)
CA (1) CA3031705A1 (fr)
CO (1) CO2019000753A2 (fr)
DK (1) DK3490560T3 (fr)
DO (1) DOP2019000019A (fr)
ES (1) ES3014630T3 (fr)
FI (2) FI3490560T3 (fr)
FR (1) FR25C1027I1 (fr)
HR (1) HRP20250157T1 (fr)
HU (2) HUE070253T2 (fr)
IL (2) IL322013A (fr)
LT (2) LT3490560T (fr)
MA (1) MA45780B1 (fr)
MX (2) MX2019001224A (fr)
NI (1) NI201900009A (fr)
PE (1) PE20190403A1 (fr)
PH (1) PH12019500135A1 (fr)
PL (1) PL3490560T3 (fr)
PT (1) PT3490560T (fr)
RS (1) RS66574B1 (fr)
SG (1) SG11201900361RA (fr)
SI (1) SI3490560T1 (fr)
SM (1) SMT202500082T1 (fr)
SV (1) SV2019005822A (fr)
UA (1) UA124972C2 (fr)
WO (1) WO2018023017A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3478286B1 (fr) 2016-06-29 2024-01-03 Tesaro, Inc. Méthodes de traitement du cancer de l'ovaire
WO2018023017A1 (fr) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate
KR20200105862A (ko) * 2017-12-27 2020-09-09 테사로, 인코포레이티드 암을 치료하는 방법
CA3100513A1 (fr) * 2018-05-16 2019-11-21 Gtx, Inc. Ligands de composes de degradation selectifs de recepteurs des androgenes (sard) et procedes d'utilisation associes
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US20240325369A1 (en) * 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
WO1987000834A1 (fr) 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Nouveaux analogues de la vitamine d
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (fr) 1989-03-09 1994-12-20 Hector F. Deluca Composes de type 19-nor-vitamine d
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
DE4021433A1 (de) 1990-07-04 1992-01-09 Schering Ag Antiandrogene mit steroid(3,2-c)pyrazol-struktur
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
DE69416419T2 (de) 1993-09-30 1999-06-10 Btg International Ltd., London Synthese von 17-(3-pyridyl) steroiden
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CA2255615C (fr) 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprenant des conjugues d'acide cis-docosahexanoique et de docetaxel
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
EP2340840B1 (fr) 1998-03-27 2012-08-29 Oregon Health Sciences University Dose pulsée d'une vitamin D pour le traitement de maladies d'hyperprolifération de la peau
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
JP2002533404A (ja) 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
ES2300323T3 (es) 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
JPWO2001081364A1 (ja) 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−１，３，５（１０）−トリエン誘導体
DE60118571T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
EP1676577A1 (fr) 2000-05-15 2006-07-05 Celgene Corporation Compositions pour le traitement du cancer contenant un inhibiteur de topoisomerase et thalidomide
CN1254234C (zh) 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
WO2002003286A1 (fr) 2000-07-05 2002-01-10 Bryan Muehlberger Systemes et procedes destines a faciliter des transactions de paiement electronique
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
EP1351678A2 (fr) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Traitement pour inhiber des lesions neoplasiques contenant de l'incensole et/ou des furanogermacrens
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
ES2323876T3 (es) 2001-04-18 2009-07-27 Euro-Celtique S.A. Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor.
EP1975164B1 (fr) 2001-04-18 2010-01-27 Euro-Celtique S.A. Composés dérivés d'octahydrobenzimidazolone comme analgésiques
UA74439C2 (uk) 2001-04-18 2005-12-15 Еро-Селтік, С.А. Сполуки спіропіразолу
WO2002091993A2 (fr) 2001-05-10 2002-11-21 Merck & Co., Inc. Modulateurs des recepteurs des oestrogenes
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
WO2003020699A2 (fr) 2001-08-30 2003-03-13 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
AU2002326823B2 (en) 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003037252A2 (fr) 2001-10-30 2003-05-08 Merck & Co., Inc. Inhibiteurs de tyrosines kinases
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
DK1472225T3 (da) 2002-02-01 2010-08-09 Euro Celtique Sa 2-Piperazinpyridiner, som er anvendelige til behandling af smerte
EP1336602A1 (fr) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20050159361A1 (en) 2002-03-11 2005-07-21 Takahito Hara Remedies for sex hormone-dependent disease
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
EP1927858B1 (fr) 2002-04-29 2013-01-09 Euro-Celtique S.A. Peptides à conformations contraintes se liant au récepteur ORL-1
EP1503757B1 (fr) 2002-05-02 2007-12-19 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
JP4463679B2 (ja) 2002-06-14 2010-05-19 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2004002983A2 (fr) 2002-06-28 2004-01-08 Euro-Celtique, S.A. Agents therapeutiques utiles pour le traitement de la douleur
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
AU2003259835A1 (en) 2002-08-15 2004-03-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CN100528167C (zh) 2002-10-23 2009-08-19 潘塔希生物科学股份有限公司 用于治疗癌症的包含雌四醇衍生物的药物组合物
EP1558609A4 (fr) 2002-10-30 2008-05-28 Merck & Co Inc Inhibiteurs de kinase
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CN1744930A (zh) 2002-12-17 2006-03-08 先灵公司 治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
WO2004062620A2 (fr) 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol utilise comme agent chimiotherapeutique
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
CA2524737A1 (fr) 2003-05-06 2005-02-24 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique aux recepteurs trail
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
TWI287010B (en) 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1867644B1 (fr) 2003-07-24 2009-05-20 Euro-Celtique S.A. Composés de hétéroaryl-tétrahydropipéridyle utiles pour traiter ou prévenir la douleur
DE602004021206D1 (de) 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PT1648880E (pt) 2003-08-01 2010-04-26 Euro Celtique Sa Agentes terapêuticos úteis para o tratamento da dor
AU2004268707A1 (en) 2003-08-27 2005-03-10 Merck Frosst Canada Ltd Cathepsin inhibitors
PL1664041T3 (pl) 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
ES2317052T3 (es) 2003-09-22 2009-04-16 Euro-Celtique S.A. Agentes terapeuticos utiles para el tratamiento del dolor.
AU2004283479A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
US7445794B1 (en) 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
US20060003950A1 (en) 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
AU2005281797B2 (en) 2004-09-10 2011-07-07 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
EP1674479A1 (fr) 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation des récepteurs Fc gamma pour optimiser l'immunothérapie
WO2006081152A2 (fr) 2005-01-24 2006-08-03 Merck & Co., Inc. Modulateurs du recepteur des oestrogenes
KR20080018874A (ko) 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
AU2006239896A1 (en) 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1909812A4 (fr) 2005-07-27 2009-11-25 Univ Florida Petits composes corrigeant un mauvais repliement des proteines et utilisations de ceux-ci
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
AU2007300734A1 (en) 2006-06-02 2008-04-03 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RNA nanoparticles and nanotubes
WO2008005268A1 (fr) 2006-06-30 2008-01-10 Schering Corporation Pipéridines substituées qui augmentent l'activité p53 et leurs utilisations
MX2009000132A (es) 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
US20080051375A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2081964A4 (fr) 2006-10-12 2012-07-11 Univ Johns Hopkins Compositions d'alginate et d'alginate-lyase et procédés d'utilisation
US20100168228A1 (en) 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2491923A3 (fr) 2007-02-15 2012-12-26 Novartis AG Combinaisons d'agents thérapeutiques pour traiter le cancer
WO2008109740A2 (fr) 2007-03-06 2008-09-12 Colby Pharmaceutical Company Composés antioxydants cationiques ciblés sur les mitochondries destinés à la prévention, à la thérapie et au traitement des maladies hyper-prolifératives, des néoplasies et des cancers
WO2009009132A1 (fr) 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Utilisation d'inhibiteurs de 17alpha-hydroxylase/c17,20-lyase pour le traitement du cancer
NZ586675A (en) * 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
MX2010011924A (es) 2008-05-07 2010-11-30 Cardioxyl Pharmaceuticals Inc Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
WO2012009475A1 (fr) 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
WO2012106514A2 (fr) 2011-02-03 2012-08-09 Pop Test Cortisol Llc Système et méthode de diagnostic et de traitement
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
PT3305285T (pt) * 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
WO2014089324A1 (fr) 2012-12-07 2014-06-12 Calitor Sciences, Llc Composés cycliques substitués et leurs procédés d'utilisation
WO2014150000A1 (fr) 2013-03-21 2014-09-25 Isp Investments Inc. Film de diacétylène sensibilisé avec un photoinitiateur et applications du film
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2015023710A1 (fr) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
US9987275B2 (en) 2014-04-23 2018-06-05 The Brigham And Women's Hospital, Inc. Targeting PARP1 for treatment of TSC and cancers
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
WO2018023017A1 (fr) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate
US11702443B2 (en) 2016-10-04 2023-07-18 Pop Test Oncology Llc Therapeutic agents and methods
US11040037B2 (en) 2016-10-04 2021-06-22 Pop Test Oncology Llc Therapeutic agents and methods
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
KR20200068689A (ko) 2017-10-11 2020-06-15 얀센 온콜로지 인크 안드로겐 박탈 요법과 함께 아비라테론 아세테이트 + 프레드니손을 투여하여 전립선암을 치료하는 방법

Also Published As

Publication number Publication date
HUE070253T2 (hu) 2025-05-28
AU2023202813A1 (en) 2023-05-25
IL264443A (en) 2019-02-28
AU2017302660B2 (en) 2023-04-20
US20230149380A1 (en) 2023-05-18
CA3031705A1 (fr) 2018-02-01
US20180028521A1 (en) 2018-02-01
SMT202500082T1 (it) 2025-03-12
ES3014630T3 (en) 2025-04-23
MX2019001224A (es) 2019-06-03
KR20240115925A (ko) 2024-07-26
SV2019005822A (es) 2019-03-28
JP7569353B2 (ja) 2024-10-17
US12383543B2 (en) 2025-08-12
BR112019001398A2 (pt) 2019-05-07
CN119606966A (zh) 2025-03-14
JP2022122920A (ja) 2022-08-23
SI3490560T1 (sl) 2025-04-30
EP4552698A2 (fr) 2025-05-14
CN109640991A (zh) 2019-04-16
US20220071979A1 (en) 2022-03-10
LTPA2025528I1 (fr) 2025-08-11
MA45780B1 (fr) 2025-03-28
WO2018023017A1 (fr) 2018-02-01
JP2024150638A (ja) 2024-10-23
RS66574B1 (sr) 2025-03-31
US20230098047A1 (en) 2023-03-30
LT3490560T (lt) 2025-02-25
PH12019500135A1 (en) 2019-10-28
CO2019000753A2 (es) 2019-02-08
NI201900009A (es) 2019-05-10
FIC20250026I1 (fi) 2025-07-21
HUS2500030I1 (hu) 2025-08-28
FR25C1027I1 (fr) 2025-09-19
US11207311B2 (en) 2021-12-28
PL3490560T3 (pl) 2025-03-24
PT3490560T (pt) 2025-03-20
EP4552698A3 (fr) 2025-07-30
FI3490560T3 (fi) 2025-02-27
JP2019522032A (ja) 2019-08-08
MX2023011187A (es) 2023-10-02
US20240000766A1 (en) 2024-01-04
HRP20250157T1 (hr) 2025-03-28
CN119606965A (zh) 2025-03-14
US20190022079A1 (en) 2019-01-24
JP7752220B2 (ja) 2025-10-09
SG11201900361RA (en) 2019-02-27
EP3490560A1 (fr) 2019-06-05
DOP2019000019A (es) 2019-09-30
US11986470B2 (en) 2024-05-21
EP3490560B1 (fr) 2025-01-22
US11992486B2 (en) 2024-05-28
PE20190403A1 (es) 2019-03-13
US20230078160A1 (en) 2023-03-16
AU2017302660A1 (en) 2019-01-24
US11986468B2 (en) 2024-05-21
US20220071980A1 (en) 2022-03-10
US11986469B2 (en) 2024-05-21
UA124972C2 (uk) 2021-12-22
DK3490560T3 (da) 2025-02-17
KR20190033599A (ko) 2019-03-29
IL322013A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3488001A4 (fr) Traitement du cancer
IL249065A0 (en) Combination therapies for the treatment of cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
PL3288581T3 (pl) Sposób leczenia nowotworu
PL3283527T3 (pl) Leczenie skojarzone nowotworów
IL284875A (en) Lasofoxifene treatment of breast cancer
EP3606531A4 (fr) Méthodes de traitement du cancer
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
IL263802A (en) Cancer treatment combinations
IL265697B1 (en) Treatment of prostate cancer
MA45129A (fr) Traitements du cancer
EP3440112A4 (fr) Méthodes de traitement du cancer
MA47408A (fr) Traitement du cancer
PT3622953T (pt) Tratamento combinado do cancro
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
EP3468548A4 (fr) Méthodes de traitement du cancer du pancréas
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
EP3389652A4 (fr) Méthodes de traitement du cancer